Advertisement

WELLESLEY HILLS, Mass., March 1, 2011 /PRNewswire/ -- Source Precision Medicine, Inc., dba SourceMDx ("SourceMDx") has assigned all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of SourceMDx creditors.

Source MDx® is an industry leader in developing simple blood tests that can consistently detect the presence and aggressiveness of cancer by measuring specific RNA transcripts in blood. RNA is an early biological measure of disease, providing a significant indicator of disease onset or progression in the blood stream before other clinical manifestations become observable. Source MDx® is the first to translate robust RNA-transcript based assays into clinically useful oncology molecular diagnostic tests using a simple, non-invasive blood test. Source MDx® tests are precise and calibrated measurements of white blood cell gene expression and track an individual's current health, disease status and response to therapy in a reproducible fashion.

The intellectual property, patents, etc. will be sold at a sealed bid sale on Friday, April 29, 2011 at noon.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@finnwarnkegayton.com or 781-237-8840. They will then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton  (www.finnwarnkegayton.com), Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy

'/>"/>

SOURCE

Advertisement
Advertisement